Insulin resistance and polycystic ovary syndrome;Insulinorésistance et syndrome des ovaires polykystiques

Gynecologie Obstetrique et Fertilite

Volumn 31, Issue 2, 2003, Pages 109-116

  Bernard, L ^a   Christin Maitre S ^a   Basille, C ^a   Chabbert Buffet, N ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

Author keywords

Biguanides; Clomiphene citrate; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

ANDROGEN RELEASE; ANOVULATION; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIA; FEMALE; FERTILITY; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN RESISTANCE; OBESITY; OVARY DISEASE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PREGNANCY COMPLICATION; PROTEIN PHOSPHORYLATION; RANDOMIZATION;

EID: 0038637744     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/S1297-9589(03)00009-2     Document Type: Article

References (38)

1. Erickson G. Polycystic ovary syndrome: the ovarian connection, in Reproductive Endocrinology, surgery and technology. In: York LRP-N, editor. 1995. p. 1141-60.
2. Vendola K, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-9.
3. Gilling-Smith C, et al. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin. Endo 1997;47:93-9.
4. Nelson V, Qin Kn KN, Rosenfield RL, Wood JR, Penning TM, Legro R, et al. The biochemical basis for increase testosterone production in thecal cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925-33.
5. Abbott D, Dumesic DA, Francks. Developmental origin of polycystic ovary syndrome, a hypothesis. J Endocrinol 2002;174:1-5.
6. Legro R, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002;78:569-76.
7. Burghen G, Givens J, Kitabchi A. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6.
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
9. Cara J, et al. Insulin-like growth factor-1 enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 1990;86:560-5.
10. Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by insulin receptor and not the type-1 insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-90.
11. Nestler J, Jakubowicz D. Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23.
12. Nestler J. Insulin regulation of human ovarian androgens. Hum Reprod 1997;12:53-62.
13. Legro R, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-9.
14. Koivunen R, et al. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001;86:2591-9.
15. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increase early insulin secretion after weight loss in obese women with polycystic ovarysyndrome. J Clin Endocrinol Metab 1995;80:2586-93.
16. Oberfield S. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome is insulin, indeed, the culprit? J Clin Endocrinol Metab 2000;85:3520-5.
17. Diamanti-Kandarakis E, et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666-73.
18. Ibanez L, et al. Sensibilization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-8.
19. Glueck C, et al. Metformin restore normal menses in oligoamenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-9.
20. Moghetti P, et al. Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: a randomized, double blind, placebo-controlled 6 months trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46.
21. Fleming R, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-74.
22. Nestler J, et al. Effects of metformin on spontaneous and clomipheneinduced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
23. Kocak M, et al. Metformin therapy improves ovulatory rates, cervical score and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-6.
24. Batukan C, Baysal BBB. Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2001;265:124-7.
25. Parsanezhad M, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gyn Obstet 2001;75:43-50.
26. Vandermolen D, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-5.
27. Sturrock N, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002;53:469-73.
28. Ng E HPC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001;16:1625-31.
29. De Leo V, et al. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72.
30. Yarali H, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002;17:289-94.
31. Stadtmauer L, et al. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-growth factors. Fertil Steril 2001;75:505-9.
32. Jakubowicz D, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor- binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovarysyndrome. J Clin Endocrinol Metab 2001;86:1126-33.
33. Glueck C, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46-52.
34. Jakubowicz D, et al. Effects of metformin on early pregnancy loss in the polycystic ovarysyndrome. J Clin Endocrinol Metab 2002;87:524-9.
35. Glueck C, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002;17:2858-64.
36. Pasquali R, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
37. Azziz R, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebocontrolled trial. J Clin Endocrinol Metab 2001;86:1232-626.
38. Mitwally M, Kuscu N, Yalcinkaya T. High ovulatory rates use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999;14:2700-3.